Aarti Pharmalabs Limited

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about the cessation of Senior Management Personnel, Shri G.M. Naidu, Manufacturing/ Sr. General Manager, due to resignation, effective August 31, 2026.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about publishing newspaper advertisements regarding dispatch to the Shareholders of Annual Report for the Financial Year 2025-26 and Notice of the 7th Annual General Meeting of the Company.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about publishing newspaper advertisements for its 7th Annual General Meeting, fixing the record date for payment of final dividend for FY 2025-26, and requesting shareholders to register their Email-Ids with their depository participants.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has announced a record date of September 15, 2026, for the payment of a final dividend of 40% (₹2.00 per equity share) for the financial year 2025-26.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call held on 14th February, 2023.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about the link to the recording of their earnings conference call for the first quarter ended June 30, 2026, which can be accessed on their website.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has released its Q1 FY27 results presentation, highlighting its 25+ years of pharmaceutical excellence, 220+ products, 500+ global clients, and 63+ patents filed. The company has a strong presence in xanthine derivatives, CDMO/CMO services, and has received accreditations from USFDA, EU GMP, EDQM, and other agencies.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has published its unaudited financial results for the quarter ended June 30, 2026, in newspapers as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange regarding the retirement of Mr. Rajendra Vallabhaji Gogri as a Non-Executive Director due to personal goals and other commitments.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange regarding 'Capacity Addition'. The company has approved capacity addition for Development of Intermediate Block at an estimated capex of Rs.149 Crores.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has announced a change in directorship, with Rashesh C. Gogri being appointed as Managing Director and Hetal Gogri Gala being appointed as Executive Director, both effective October 1, 2026, subject to shareholder approval. The company also approved the reconstitution of the Audit Committee, Corporate Social Responsibility Committee, and Stakeholders Relationship Committee, and announced a capacity addition for the development of an intermediate block at an estimated capex of Rs. 149 Crores.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and has also approved several key decisions, including the appointment of new managing and executive directors, capacity addition, and reconstitution of various committees.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about the schedule of an earnings conference call to discuss the Q1 FY27 financial results.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of securities and listing on stock exchanges.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has inaugurated a new state-of-the-art manufacturing block at Tarapur Unit 5, Maharashtra, to expand its production capacity, increasing its total capacity to 9600 TPA and making it one of the top 3 Xanthine derivatives manufacturers globally.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has informed the Exchange regarding allotment of 22,062 securities pursuant to ESOP/ESPS at its meeting held on Jun 24, 2026, increasing the paid-up Equity share capital of the Company to Rs. 45,33,99,065.

Aarti Pharmalabs Limited

Aarti Pharmalabs Limited has closed its trading window for dealing in its securities from July 1, 2026, until 48 hours after the declaration of its financial results for the quarter ending June 30, 2026.